Dr. Den Discusses the Future of Prostate Cancer Research

Robert B. Den, MD
Published: Wednesday, Apr 25, 2018



Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.

The field of prostate cancer has gone through an explosion within the last 5 to 10 years with the FDA approvals of multiple agents. These agents have shown activity in late-stage disease, and subsequent trials have begun to show activity in earlier-stage disease, Den says. This has garnered a lot of hope for the treatment of patients with prostate cancer, as these agents are now proven to be active earlier in the disease state, and may increase survival.

Den says that these advances have led more people to become actively involved in prostate cancer research. DNA-damaging agents, such as PARP inhibitors and DNA-PK inhibitors, are being investigated, and phase II trials have shown that selecting patients by mutation may ensure benefit. This is a new area of prostate cancer research that will soon be manifested in clinical benefit for patients, Den concludes.
SELECTED
LANGUAGE


Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.

The field of prostate cancer has gone through an explosion within the last 5 to 10 years with the FDA approvals of multiple agents. These agents have shown activity in late-stage disease, and subsequent trials have begun to show activity in earlier-stage disease, Den says. This has garnered a lot of hope for the treatment of patients with prostate cancer, as these agents are now proven to be active earlier in the disease state, and may increase survival.

Den says that these advances have led more people to become actively involved in prostate cancer research. DNA-damaging agents, such as PARP inhibitors and DNA-PK inhibitors, are being investigated, and phase II trials have shown that selecting patients by mutation may ensure benefit. This is a new area of prostate cancer research that will soon be manifested in clinical benefit for patients, Den concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x